43.83
price up icon0.00%   0.00
after-market Dopo l'orario di chiusura: 43.78 -0.05 -0.11%
loading
Precedente Chiudi:
$43.83
Aprire:
$43.93
Volume 24 ore:
10.10M
Relative Volume:
0.73
Capitalizzazione di mercato:
$89.21B
Reddito:
$47.70B
Utile/perdita netta:
$5.07B
Rapporto P/E:
17.68
EPS:
2.4784
Flusso di cassa netto:
$14.58B
1 W Prestazione:
+0.46%
1M Prestazione:
-0.75%
6M Prestazione:
-9.98%
1 anno Prestazione:
-17.18%
Intervallo 1D:
Value
$43.58
$43.94
Intervallo di 1 settimana:
Value
$43.34
$45.23
Portata 52W:
Value
$42.96
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Nome
Bristol Myers Squibb Co
Name
Telefono
(609) 252-4621
Name
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Dipendente
34,100
Name
Cinguettio
@BMSNEWS
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BMY's Discussions on Twitter

Confronta BMY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
43.83 89.21B 47.70B 5.07B 14.58B 2.4784
Drug Manufacturers - General icon
LLY
Lilly Eli Co
825.45 736.03B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
190.40 463.72B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.99 403.22B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.36 254.84B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.49 217.76B 63.43B 16.42B 14.72B 6.4861

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-05 Downgrade Daiwa Securities Outperform → Neutral
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-04-22 Iniziato Piper Sandler Overweight
2024-12-16 Aggiornamento Jefferies Hold → Buy
2024-12-10 Ripresa BofA Securities Neutral
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-13 Aggiornamento Daiwa Securities Neutral → Outperform
2024-11-12 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-25 Downgrade Citigroup Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-07-29 Downgrade Barclays Overweight → Equal Weight
2024-03-11 Downgrade Societe Generale Buy → Hold
2024-02-06 Downgrade Redburn Atlantic Buy → Neutral
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-15 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-02 Downgrade Daiwa Securities Outperform → Neutral
2023-10-27 Downgrade BMO Capital Markets Outperform → Market Perform
2023-10-27 Aggiornamento HSBC Securities Reduce → Hold
2023-10-27 Downgrade William Blair Outperform → Mkt Perform
2023-10-20 Ripresa UBS Neutral
2023-07-14 Iniziato HSBC Securities Reduce
2023-07-10 Iniziato SVB Securities Market Perform
2023-06-28 Iniziato Daiwa Securities Outperform
2023-03-06 Iniziato Jefferies Hold
2023-01-17 Iniziato Cantor Fitzgerald Overweight
2022-11-18 Iniziato Credit Suisse Neutral
2022-10-10 Downgrade Guggenheim Buy → Neutral
2022-09-14 Downgrade Berenberg Buy → Hold
2022-06-03 Downgrade Raymond James Outperform → Mkt Perform
2022-04-06 Ripresa Morgan Stanley Underweight
2021-12-17 Iniziato Goldman Buy
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-11-01 Downgrade Argus Buy → Hold
2021-07-27 Ripresa Truist Buy
2021-04-30 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-04-13 Aggiornamento Truist Hold → Buy
2020-11-16 Aggiornamento Societe Generale Hold → Buy
2020-11-10 Ripresa Bernstein Mkt Perform
2020-11-06 Downgrade Gabelli & Co Buy → Hold
2020-10-19 Aggiornamento Guggenheim Neutral → Buy
2020-09-29 Iniziato Berenberg Buy
2020-07-28 Iniziato Raymond James Outperform
2020-04-02 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-01-06 Ripresa Citigroup Buy
2019-12-13 Aggiornamento Argus Hold → Buy
2019-11-22 Ripresa Morgan Stanley Equal-Weight
2019-10-17 Ripresa BofA/Merrill Buy
2019-08-14 Aggiornamento Atlantic Equities Neutral → Overweight
2019-05-28 Iniziato Goldman Buy
2019-05-20 Downgrade Argus Buy → Hold
2019-05-03 Aggiornamento Barclays Equal Weight → Overweight
2019-05-03 Ripresa JP Morgan Overweight
2019-01-15 Aggiornamento Societe Generale Sell → Buy
2018-10-22 Downgrade Citigroup Buy → Neutral
Mostra tutto

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

pulisher
08:14 AM

How Bristol Myers Squibb Company Celegne Contingent stock trades under stagflationJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - newser.com

08:14 AM
pulisher
11:23 AM

Bristol Myers Squibb reports positive early results from CAR T therapy trial - Investing.com

11:23 AM
pulisher
11:00 AM

Bristol Myers Squibb (NYSE: BMY) shares Phase 1 CD19 CAR T in 71 autoimmune patients - Stock Titan

11:00 AM
pulisher
03:35 AM

BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 (BMYMP.US) is scheduled to release its earnings report before the market opens on October 30. - 富途牛牛

03:35 AM
pulisher
Oct 24, 2025

Applying chart zones and confluence areas to Bristol Myers Squibb CompanyJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - The Globe and Mail

Oct 24, 2025
pulisher
Oct 24, 2025

Is Bristol Myers Squibb Company stock resilient to inflationPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com

Oct 24, 2025
pulisher
Oct 23, 2025

Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Risk adjusted return profile for Bristol Myers Squibb Company Equity Right analyzedPortfolio Profit Report & AI Enhanced Trading Alerts - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Forecasting Bristol Myers Squibb Company Equity Right price range with options dataMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Will Bristol Myers Squibb Company stock deliver better than expected guidanceTrade Risk Summary & Low Drawdown Trading Strategies - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Can Bristol-Myers Squibb’s Innovation Push Reverse Its Stock Slide? - AD HOC NEWS

Oct 23, 2025
pulisher
Oct 23, 2025

Is Bristol Myers Squibb Company (BRM) stock cheap vs fundamentalsJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Bristol-Myers $450M Payment Dispute Heads To Arbitration - Law360

Oct 22, 2025
pulisher
Oct 22, 2025

Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks - The Motley Fool

Oct 22, 2025
pulisher
Oct 21, 2025

Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Trend analysis for Bristol Myers Squibb Company this week2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

The Play On Bristol-Myers Squibb (NYSE:BMY) - Seeking Alpha

Oct 21, 2025
pulisher
Oct 21, 2025

Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock - Insider Monkey

Oct 21, 2025
pulisher
Oct 21, 2025

Small Cell Lung Cancer Market Research 2025-2035: Growth Driven by Advancements in Novel Therapies, Including Immunotherapies, Targeted Therapies, and Combination Treatments - GlobeNewswire Inc.

Oct 21, 2025
pulisher
Oct 21, 2025

How high can Bristol Myers Squibb Company stock goJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Will Bristol Myers Squibb Company Celegne Contingent stock benefit from Fed rate cuts2025 Technical Overview & High Accuracy Swing Entry Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Bristol-Myers’ $450 Million Earnout Pay Fight Sent to Arbitrator - Bloomberg Law News

Oct 20, 2025
pulisher
Oct 20, 2025

US CBO says orphan drug exemption could add $6 billion to cost of Trump's 'Big Beautiful Bill' - Reuters

Oct 20, 2025
pulisher
Oct 20, 2025

Can Bristol-Myers Squibb Stock Recover After Steep Decline? - AD HOC NEWS

Oct 20, 2025
pulisher
Oct 20, 2025

Bristol-Myers Squibb (BMY) Investor Outlook: Navigating a 21.59% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews

Oct 20, 2025
pulisher
Oct 18, 2025

Can Bristol Myers Squibb Company stock hit record highs againMarket Performance Recap & Expert Verified Movement Alerts - newser.com

Oct 18, 2025
pulisher
Oct 17, 2025

Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Resul - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb, SystImmune report data from lung cancer trial - Seeking Alpha

Oct 17, 2025
pulisher
Oct 17, 2025

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Is Bristol Myers Squibb Company Equity Right building a consolidation baseMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com

Oct 17, 2025
pulisher
Oct 16, 2025

Does Bristol Myers Stock Offer Value as AI Data-Sharing Alliance Makes Headlines? - simplywall.st

Oct 16, 2025
pulisher
Oct 16, 2025

insitro and Bristol Myers Squibb (BMY) Advance ALS Research with New AI-Powered Collaboration - Yahoo Finance

Oct 16, 2025
pulisher
Oct 15, 2025

Bristol Myers Squibb Launches Kopozgo (Mavacamten) In IndiaStatement - TradingView

Oct 15, 2025
pulisher
Oct 15, 2025

What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga

Oct 15, 2025
pulisher
Oct 15, 2025

Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Orbital Therapeutics Deal - Insider Monkey

Oct 15, 2025
pulisher
Oct 15, 2025

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace

Oct 15, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com

Oct 14, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com Australia

Oct 14, 2025
pulisher
Oct 14, 2025

BMY Collaboration Advances ALS Treatment Development - GuruFocus

Oct 14, 2025
pulisher
Oct 14, 2025

$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers Squibb describes new FAK degradation inducers - BioWorld MedTech

Oct 14, 2025
pulisher
Oct 14, 2025

11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review

Oct 14, 2025
pulisher
Oct 14, 2025

What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma

Oct 14, 2025
pulisher
Oct 14, 2025

What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl

Oct 14, 2025
pulisher
Oct 14, 2025

Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com

Oct 14, 2025

Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general SNY
$51.64
price up icon 4.28%
drug_manufacturers_general PFE
$24.76
price up icon 0.36%
$120.94
price up icon 0.17%
$291.76
price down icon 0.39%
drug_manufacturers_general NVO
$52.96
price down icon 0.51%
drug_manufacturers_general MRK
$87.49
price up icon 0.36%
Capitalizzazione:     |  Volume (24 ore):